Business
Half-year Financial Report
Scancell Holdings plc reported interim results for the six months ended 31 October 2025, with an operating loss of £8.9 million, an improvement from £10.5 million in the prior year, and a cash balance of £8.6 million. The company's lead product, iSCIB1+, demonstrated a 74% Progression Free Survival at 16 months in advanced melanoma, leading to FDA clearance for a Phase 3 trial planned to commence in 2026. Modi-1 data for head and neck and renal cell cancer is anticipated in H1 2026, and the company has established GlyMab Therapeutics Limited to focus on antibody assets. The company expects its cash runway to extend to H2 2026. Disclaimer*
About this update from Scancell Holdings Plc
29 January 2026 Scancell Holdings plc ("Scancell", the "Company" or the "Group") Interim Results for the six months ended 31 October 2025 Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its unaudited financial results for the six-month period to 31 October 2025. Highlights (including post period) DNA ImmunoBody ® iSCIB1+ (SCOPE trial): · iSCIB1+, the lead product from Scancell's DNA ImmunoBody® platform, demonstrated potentially best-in-class efficacy and durability, and strong Progression Free Survival (PFS) with checkpoint inhibitors (CPIs) in a Phase 2 trial in advanced melanoma: o 74% PFS at 16 months for iSCIB1+ with the double CPIs of nivolumab and ipilimumab o A 24%-point improvement in PFS over real-world standard of care (SoC) and historic controls o Strong PFS data continues to be collected across key subgroups o Selection marker identified to enrich the phase 3 trial for responders. · The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for a registrational Phase 3 trial of iSCIB1+ ImmunoBody® in advanced melanoma, with PFS as the agreed surrogate endpoint. · Completed 140-patient SCOPE Phase 2 study evaluating ImmunoBody® immunotherapies (SCIB1 and iSCIB1+) in combination with nivolumab plus ipilimumab in previously untreated unresectable stage IIIB/IV melanoma. · Continued evaluation of all financing options, including partnering discussions, for the Phase 3 development of iSCIB1+ for the treatment of advanced melanoma. · A global Phase 3 registrational study planned to commence in 2026, with potential read-out and commercialisation in 2029. Moditope® Modi-1 (ModiFY trial): · Modi-1, a citrullinated peptide off-the-shelf vaccine, is showing early promise in a Phase 2 study for the treatment of squamous cell cancer of head and neck (SSCHN) and renal cell carcinoma (RCC). · The study will assess whether Modi-1 in combination with CPIs improves outcomes in these indications against the current SoC. · &...
View stock analysis, news, and events for Scancell Holdings Plc